Regenxbio (RGNX) Tops Q4 EPS by $1.96

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of $6.67, $1.96 better than the analyst estimate of $4.71. Revenue for the quarter came in at $398.7 million versus the consensus estimate of $271.74 million.

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $849.3 million as of December 31, 2021 to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into 2025.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in